探索与capmatinib相关的耳毒性:来自FDA不良事件报告系统 (FAERS) 数据库的真实世界数据分析的见解
Yuhao Lin1, Siqi Xu1, Muling Deng1
1Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, People's Republic of China.
Clinical epidemiology
|June 9, 2025
概括
这项研究确定了Capmatinib,一种肺癌药物的意想不到的不良药物反应 (ADR),包括听力损失. 建议进一步监测Capmatinib在实际使用中的安全性.
科学领域:
- 药物监督 药物监督 药物监督
- 在瘤学瘤学.
- 药品安全 药品安全
背景情况:
- 卡普马提尼布是FDA批准的非小细胞肺癌 (NSCLC) 的MET外显子14突变 (METex14).
- 卡普马提尼布的现实安全数据有限.
- 本研究使用FDA不良事件报告系统 (FAERS) 调查Capmatinib的显著不良药反应 (ADR).
研究的目的:
- 为了识别和描述与Capmatinib相关的显著不良药物反应 (ADRs).
- 探索药物标签上以前未记录的潜在安全信号.
- 为加强对卡普马丁尼布治疗的临床监测提供见解.
主要方法:
- 使用四种主要算法进行不成比例分析:ROR,PRR,BCPNN和EBGM.
- 根据所有算法的共识,将不良事件 (AE) 分类为药物不良反应 (ADR).
- 从FAERS数据库分析了1767例与Capmatinib相关的病例.
主要成果:
- 在14个系统器官类别 (SOC) 中,在首选术语 (PT) 层面确定了38个ADR.
- 检测到意想不到的"耳朵和迷宫障碍" (SOC),包括"低听力"和"聋" (PTs).
- 这些与耳毒性相关的事件在当前的Capmatinib药物标签上没有具体说明.
结论:
- 卡普马提尼布与意想不到的副作用有关,特别是耳毒性.
- 这些发现强调了监测与听力相关的不良事件的重要性.
- 需要进一步的研究来了解这些意想不到的副作用的机制.
相关概念视频
Pharmacovigilance
2.0K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
2.0K
Therapeutic Drug Monitoring: Affecting Factors
438
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
438
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
Kaplan-Meier Approach
807
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
807


